Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder

Immune dysregulation is implicated in major depressive disorder (MDD), but its links to clinical features and in vivo brain phenotypes remain uncertain. We examined ten plasma biomarkers in 36 unmedicated MDD patients and 48 control participants using high-sensitivity immune profiling at baseline, alongside PET/MR imaging of brain serotonin transporter (SERT) binding and regional structural measures. Patients underwent three months of antidepressant treatment and were followed up with MR imaging. Glial fibrillary acidic protein (GFAP) was higher in MDD patients ({beta} = 0.66, 95% CI 0.22 - 1.

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.